VerAvanti Inc.

VerAvanti's SFE (Scanning Fiber Endoscope) technology improves imaging accuracy and safety, helping clinicians diagnose early in cardiology and neurosurgery.

[VerAvanti Inc. @VerAvanti]

2026 disease. 2010 eyes.

PAD affects 113M people today, projected to reach 360M by 2050. Procedures evolved. Imaging did not.

IVUS can reduce amputations by 31%, yet PAD imaging adoption remains limited.

Read our breakdown of the PAD imaging gap: https://t.co/TtVa3SEPKn

[VerAvanti Inc. @VerAvanti]

What if lung biopsy isn’t limited by finding the lesion—but reaching it?

Navigation has improved. Yield hasn’t.
Not visibility. Access.
Beyond ~Gen 6, airways ~2 mm. Scopes are 3–4 mm.
You can localize—and still not reach.

Read details in our new blog:
https://t.co/SNO0lanmXQ.

[VerAvanti Inc. @VerAvanti]

Billions are being invested in calcified disease treatment.

But intravascular imaging still isn’t used in most PCI cases. That doesn’t add up.

This isn’t an evidence gap.
It’s a workflow problem.

We break down what’s driving the gap in our new blog: https://t.co/iyOpr6wSLj

[VerAvanti Inc. @VerAvanti]

VerAvanti is a finalist for Innovation of the Year at the 2026 GeekWire Awards!

CEO Gerald McMorrow shares why this recognition matters and the problem we’re solving in intravascular procedures.

Voting runs through April 16. Thank you for your support.

https://t.co/igKqOFhaxL

[VerAvanti Inc. @VerAvanti]

Voting closes in TWO WEEKS.

We’re a finalist for Innovation of the Year at the GeekWire Awards. If you want to support what we’re building, we’d truly appreciate your vote.

Vote here: https://t.co/pcHpmXKxoo]
Takes 15 seconds. Thank you!

#GeekWireAwards #MedTech #SeattleTech

[VerAvanti Inc. @VerAvanti]

Ovarian cancer isn’t a treatment problem.
It’s a detection problem.

91% vs 30% survival — timing is everything.

We still can’t reliably image where it starts.

That gap is solvable.

We break it down here:
https://t.co/ONDczcDSPV

[VerAvanti Inc. @VerAvanti]

We’re proud to be a finalist at the 2026 GeekWire Awards!

In intravascular procedures, physicians often can’t see what’s ahead—and that uncertainty matters.

We’re working to change that!

Vote for VerAvanti:
https://t.co/pcHpmXKxoo

[VerAvanti Inc. @VerAvanti]

Ultra-low contrast PCI shows complex procedures can be done with <20 mL of contrast for patients with severe CKD.

But it exposes a deeper problem: today’s imaging tools were never designed to guide PCI without contrast.

What needs to change?

Read more: https://t.co/PrMw5xbb6e

[VerAvanti Inc. @VerAvanti]

How small is VerAvanti’s Scanning Fiber Endoscope (SFE)?

Just 1 mm in diameter.

Coronary arteries are only 2–4 mm wide. At that scale, millimeters determine whether you can advance.

Precision enables confidence.
Confidence changes outcomes.

#IntravascularImaging #MedTech

[VerAvanti Inc. @VerAvanti]

A surgeon advancing a catheter toward a brain clot often can’t see what’s directly ahead of the tip.

That’s not a failure of skill. It’s a failure of tools.

VerAvanti is building a forward-looking eye for catheters.

Read the full blog: https://t.co/QXHKCscerv

[VerAvanti Inc. @VerAvanti]

The hardest moments in complex PCI happen before the stent: Advancing wires without seeing the next millimeter.

IVUS and OCT image around the catheter, not ahead.
That blind spot still shapes the highest-risk decisions in intervention.

Read Full blog: https://t.co/k3iK99Hvwt

[VerAvanti Inc. @VerAvanti]

VerAvanti was proud to join #WHX2026 and connect with physicians and partners worldwide.

Thank you to everyone who visited our booth. There are more to come as we advance toward key regulatory milestones.

#WHX #WHX2026 #Cardiology #VerAvanti #SFE

[VerAvanti Inc. @VerAvanti]

World Health Expo is just one week away!

Meet VerAvanti at WHX Dubai 2026 to see how we’re advancing real-time, high-resolution intravascular visualization for more confident clinical decision-making.

📍 South Hall 11, Booth D73
📅 Feb 9–12, Dubai
See you in Dubai!

[VerAvanti Inc. @VerAvanti]

Heart attacks aren’t always about cholesterol.
Researchers found bacterial DNA inside coronary plaques.

But current imaging shows structure, not biology.

See how SFE could reveal dangerous plaques before they rupture, read the full blog here: https://t.co/P96KOUCRfE

[VerAvanti Inc. @VerAvanti]

VerAvanti will be exhibiting at WHX – World Health Expo Dubai 2026.

Feb 9–12
Dubai Exhibition Centre
South Hall 11
Booth D73

Come see what real-time intravascular visualization looks like and how it will redefine intravascular decision-making. Meet VerAvanti at WHX 2026!

[VerAvanti Inc. @VerAvanti]

VerAvanti will be at PRISM PCI CONCLAVE 2026, celebrating 50 years of PCI!

Keynote: Dr. Luis Savastano, “Paradigm Shift in Intravascular Imaging” featuring VerAvanti ltime Coronary Angioscopy

📅 Sat, Jan 17, 2026 | 🕥 10:30–11:00
📍 Meril Academy, Vapi, India

Let’s connect!

[VerAvanti Inc. @VerAvanti]

In PCI, visibility is everything.

For complex wiring, stent placement, and apposition checks—clinicians need forward-looking imaging, not artifacts.

VerAvanti’s SFE delivers:
✓ Real-time forward view
✓1080p color
✓~1mm probe
✓single-use sterile

#cardiologist #pci #SFE

[VerAvanti Inc. @VerAvanti]

Bifurcation PCI remains highly challenging, due to limited forward visibility with current imaging.

At VerAvanti, we’re exploring how forward-looking SFE imaging could change what clinicians see, when it matters most.

Our new blog: Read more here→https://t.co/s4kM46Chmh

[VerAvanti Inc. @VerAvanti]

Happy Holidays from VerAvanti!

Thanks to our partners, collaborators, and clinicians for being part of our journey. We remain committed to advancing intravascular imaging technologies and supporting precise vascular care.

Wishing you a joyful holiday and a bright New Year!

[VerAvanti Inc. @VerAvanti]

We’re Hiring: Catheter Engineer

VerAvanti is seeking a Catheter Engineer in Bothell, WA to help develop precision imaging catheters for our Scanning Fiber Endoscope.

Micro-assembly, tooling, SolidWorks, and ISO 13485 experience preferred.

Apply here: https://t.co/idP7JC950Q